Optimizing hypertension management in clinical practice (Q36568468)

15 August 2017

1 reference

title

Optimizing hypertension management in clinical practice (English)

1 reference

15 August 2017

Heagerty A

1 reference

15 August 2017

publication date

10 August 2006

1 reference

Journal of Human Hypertension

15 August 2017

published in

1 reference

15 August 2017

1 reference

15 August 2017

1 reference

15 August 2017

page(s)

841-849

1 reference

How important is optimal blood pressure control?

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Recent hypertension trials: implications and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Hypertension awareness, treatment and control in the community: is the 'rule of halves' still valid?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Update on the management of hypertension: recent clinical trials and the JNC 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The essence of effective treatment and compliance is simplicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Controversies in hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Atenolol in hypertension: is it a wise choice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Angiotensin-II receptor blockers: benefits beyond blood pressure reduction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Angiotensin II and trials of cardiovascular outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Adverse effects of the angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

A noninferiority comparison of valsartan/hydrochlorothiazide combination versus amlodipine in black hypertensives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Angiotensin II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

More heat to support aggressive blood pressure lowering: the FEVER study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The ongoing telmisartan alone and in combination with ramipril global endpoint trial program

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The importance of blood pressure control in the patient with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Compliance and persistence with newer antihypertensive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Rationale for combination therapy in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Combination drug treatment of hypertension: have we come full circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Angiotensin II receptor antagonists alone and combined with hydrochlorothiazide: potential benefits beyond the antihypertensive effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Effects of valsartan/hydrochlorothiazide and amlodipine on ambulatory blood pressure and plasma norepinephrine levels in high-risk hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-gro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Optimizing medication adherence in older persons with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

How can we improve adherence to blood pressure-lowering medication in ambulatory care? Systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Improving patient compliance: a major goal in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Patient adherence and medical treatment outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Four-Year persistence patterns among patients initiating therapy with the angiotensin II receptor antagonist losartan versus other artihypertensive drug classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Patient Adherence With Amlodipine, Lisinopril, or Valsartan Therapy in a Usual-Care Setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Practice Guidelines For Primary Care Physicians

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

Angiotensin-Converting Enzyme Inhibitors and Calcium Channel Blockers for Coronary Heart Disease and Stroke Prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

The determinants of hypertension awareness, treatment, and control in an insured population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Blood-pressure control in the hypertensive population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Treatment for Newly Diagnosed Hypertension: Patterns of Prescribing and Antihypertensive Effectiveness in the UK

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Control of high blood pressure in primary health care

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Physicians' knowledge, attitudes, and practice of pharmacologic treatment of hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Hypertension guidelines and their limitations--the impact of physicians' compliance as evaluated by guideline awareness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Lifestyle modification to improve blood pressure control in individuals with diabetes: is physician advice effective?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Longitudinal Study on Hypertension Control in Primary Care: The Insubria Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1002079

7 January 2021

Identifiers

DOI

10.1038/SJ.JHH.1002079

1 reference

15 August 2017

1 reference